Nanoscience Technologies Rated 'Speculative Buy/4' By Investrend Research Analyst Oren Meytes, CFA
The full report is at http://www.investrendresearch.com. In it, the analyst also noted that NANS "is a pure play Nanotechnology company that has exclusively licensed cutting edge intellectual property from New York University (by far the largest shareholder with 44.40% holdings) with the intent of commercializing the raw basic science into money making applications. The technology, which has been developed by Prof. Nadrian "Ned" C. Seeman (an internationally recognized scientist and pioneer in DNA nanotechnology) could potentially serve as a platform for a broad range of next generation nanotechnology applications.
“C. Seeman (an internationally recognized scientist and pioneer in DNA nanotechnology) could potentially serve as a platform for a broad range of next generation nanotechnology applications.”
Nanotechnology is hailed as having the potential to increase the efficiency of energy consumption, help clean the environment, and solve major health problems.
Seeman's research is focused on this major challenge of precisely manipulating the nano sized particles to form useful products and applications. The methods, which he employs, are based on using the DNA molecule as the basic structural element in the assembly of objects, devices and crystalline structures on the nanometer scale. In that - his research could possibly become a cornerstone of next generation Nanotechnology applications.
It is apparent that the market gives a significant value to comparable companies' Intellectual Property. Both Arrowhead and Nanosys have a market capitalization that is many tens of millions more than their tangible assets.
There is a real science and a real story behind the company. And this story is about to be "megaphoned" to the public early next year with a major media campaign.
An InvestorPower(TM) page has been created regarding the company at http://www.investrend.com/company/list.asp?sPathParam=yes.
Investrend Research has been the leading independent equity research publishing and distribution program since 1996, with over 75 qualified professional analysts posting more than 1,000 reports to date. Anyone may enroll a company in the Investrend platforms. Enrollment fees for the Wall Street research platform, Investrend's most in-depth analytics coverage, are $43,840, which is being paid by the company and Maplehurst Capital, a third party. Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage.
The company has also been enrolled in the shareholder-monitoring program by the Shareholders Research Alliance (http://www.shareholdersresearch.com), established to eliminate conflict and bias, and Investrend subscribes to the exacting "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com.
Anyone interested in receiving alerts regarding Nanotechnology research or webcasts should e-mail email@example.com with "NANS" in the subject line, or click on http://www.investrend.com/contact.asp.